Cagrisema (5mg+5mg)

Name:  Lynn
Wechat：  15914422644

Tel：+86  15914422644

Whatsapp: +852 6252 8290

Email：    guangsheng 5   @zgguangsheng.com

I. Core Components & Properties

II. Mechanism of Action

1. Dual - Pathway Satiety Enhancement: Semaglutide acts on the GLP - 1 receptor in the brain to reduce hunger signals, while cagrilintide activates central amylin receptors to boost the sense of fullness, which together powerfully suppresses appetite.
2. Gastrointestinal Regulation: Both components work together to delay gastric emptying, extending the duration of satiety after meals and reducing overall caloric intake.
3. Metabolic & Glycemic Control: Semaglutide improves insulin sensitivity and lowers blood glucose by reducing glucagon secretion. Cagrilintide helps stabilize postprandial blood sugar and reduces the risk of blood sugar spikes, thus optimizing overall metabolic health.
4. Synergistic Weight Loss: The complementary effects of the two ingredients lead to greater weight - loss results than using either drug alone, with Phase III data showing an average weight loss of 22.7% over 68 weeks.

III. Clinical Efficacy (Key Trial Data)

1. Obesity (REDEFINE 1, Phase III): In a 68 - week trial of adults with obesity (BMI ≥30 kg/m²) without diabetes, participants who received the 5mg+5mg dose had an average weight loss of 22.7% (vs. 3.4% with placebo); 40.4% of patients lost over 25% of their body weight, and more than half achieved a non - obese BMI.
2. Type 2 Diabetes (Phase II): It significantly improved glycemic control, increased the time blood glucose was in the target range, and reduced HbA1c while promoting weight loss. It outperformed semaglutide monotherapy in both weight and glucose metrics.
3. Safety & Tolerability: The main adverse events are mild - to - moderate gastrointestinal symptoms (nausea, diarrhea, constipation, vomiting), with an incidence of about 80% in trials, mostly resolving within 1–2 weeks of dose escalation. Severe rare events may include hypoglycemia (rare when used alone), pancreatitis, and allergic reactions; close monitoring is required.